跳至主要内容
临床试验/NCT04612868
NCT04612868已完成不适用

Pivotal Prospective Clinical Trial to Demonstrate the Efficacy and Safety of AEYE-DS Software Device for Automated Diabetic Retinopathy Detection From Digital Fundoscopic Images

AEYE Health Inc2 个研究点 分布在 1 个国家目标入组 531 人开始时间: 2020年10月16日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
531
试验地点
2
主要终点
Sensitivity and Specificity, Based on Two Macula-centered Images (One Image From Each Eye of the Patient)

研究概览

简要总结

AEYE-DS is a software device developed to increase compliance with diabetic retinopathy screening by automatically detecting more-than-mild diabetic retinopathy from digital fundus images using Artificial Intelligence (AI)-based software. This study has been designed to validate the safety and efficacy of the device at primary care and other point of care sites.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female
  • Documented diagnosis of diabetes mellitus, meeting the criteria established by the American Diabetes Association (ADA) and World Health Organization (WHO).
  • Understand the study and volunteer to sign the informed consent

排除标准

  • Uncorrectable vision loss (e.g., with the use of eyeglasses), blurred vision, or floaters.
  • Diagnosed with macular edema, severe non-proliferative retinopathy, proliferative retinopathy, radiation retinopathy, or retinal vein occlusion.
  • History of laser treatment of the retina or injections into either eye, or any history of retinal surgery.
  • Currently participating in another investigational eye study and actively receiving investigational product for Diabetic Retinopathy (DR) or Diabetic Macular Edema (DME).
  • Participant has a condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure or glycemic control, microphthalmia or previous enucleation).
  • Participant is contraindicated for imaging by fundus imaging systems used in the study:
  • Participant is hypersensitive to light
  • Participant recently underwent photodynamic therapy (PDT)
  • Participant is taking medication that causes photosensitivity
  • Participant has a history of angle-closure glaucoma or narrow anterior chamber angles

结局指标

主要结局

Sensitivity and Specificity, Based on Two Macula-centered Images (One Image From Each Eye of the Patient)

时间窗: 1 day

Sensitivity and specificity of the AEYE-DS device to detect mtmDR on digital funduscopic images, acquired by the Topcon NW400 fundoscopy device, based on two macula-centered images (one image from each eye of the patient). Sensitivity and specificity were calculated by comparing the output results of the AEYE-DS device to the ground truth (diagnostic determination by an independent, blinded panel of expert ophthalmologists at a reading center). The worst of two eyes was compared with the AEYE-DS output at the participant level.

次要结局

  • Sensitivity and Specificity, Based on Four Images (One Macula Centered Image and One Optic Disc Centered Image Per Eye)(1 day)
  • Imageability, Based on Two Macula-centered Images (One Image From Each Eye of the Patient)(1 day)
  • Imageability, Based on Four Images (One Macula Centered Image and One Optic Disc Centered Image Per Eye)(1 day)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Efficacy and Safety of AEYE-DS Software Device for... | 临床试验